RVU 305
Alternative Names: RVU-305Latest Information Update: 25 Oct 2024
At a glance
- Originator Ryvu Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action PRMT5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours